Big4Bio:Boston

@big4bioBOS

Part of the life science hub coverage network. Subscribe to the Big4Bio:Boston daily newsletter for FREE:

Vrijeme pridruživanja: prosinac 2013.

Tweetovi

Blokirali ste korisnika/cu @big4bioBOS

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @big4bioBOS

  1. prije 6 sati

    How did Boston’s industry fare in 2019? Read the 2019 Year-in-Review for Boston:

    Poništi
  2. proslijedio/la je Tweet
    prije 8 sati

    1,300+ scientists and clinicians analyzed 2,600+ whole genomes of 38 different tumor types over the last six years, completing the most comprehensive study of whole genomes to date and significantly improving our understanding of cancer.

    Poništi
  3. proslijedio/la je Tweet

    On BioGenesis podcast, Kwadwo Owusu-Boaitey of the Reddien lab recalls how tumor board meetings at Greenebaum Cancer Center helped shape his decision to pursue an MD-PhD with and become a physician-scientist:

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet

    Magenta Therapeutics is pleased to announce the expansion of our senior leadership team: Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as SVP, Head of Manufacturing. More here:

    Poništi
  5. prije 7 sati
    Poništi
  6. 4. velj

    "Today’s approval of Ayvakit brings forward a new standard of care for patients with PDGFRA exon 18 mutant GIST, a genomically defined population that previously had very limited treatment options."

    Poništi
  7. 4. velj
    Poništi
  8. proslijedio/la je Tweet
    4. velj

    Feb 27 Event . Join a lively discussion around planning for a transition from dev stage to commercial company. Find out what to do before, during and after receiving that sought-after approval.

    Poništi
  9. 4. velj

    FREE VENTURE FUNDING HAPPY HOUR 🍺 TONIGHT : Venture Funding MUST be part of your success plan! Learn from noted investors. Network. PLUS join the info session. See you after work! RSVP:

    Poništi
  10. proslijedio/la je Tweet
    4. velj

    More disputes on AI-style drug discovery, and hopes that the field can eventually get past this phase:

    Poništi
  11. 3. velj
    Poništi
  12. 3. velj
    Poništi
  13. proslijedio/la je Tweet
    30. sij

    "The truth is, a gene mutation alone isn’t enough to explain whether someone will develop cancer. There are millions of other variants—DNA differences..." How so-called "junk DNA" affects cancer risk, J Quackenbush ht

    Poništi
  14. 3. velj

    FREE VENTURE FUNDING HAPPY HOUR 🍺 TOMORROW : Venture Funding MUST be part of your success plan! Learn from noted investors. Network. PLUS join the info session. See you after work! RSVP:

    Poništi
  15. 3. velj

    Sandra Horning, M.D. To Join Board of Directors "Former /Roche Chief Medical Officer and Head of Global Product Development will bring extensive global biopharma expertise to support Moderna’s late-stage development efforts"

    Poništi
  16. proslijedio/la je Tweet
    3. velj

    Now is your chance to save $400 off your PEGS Summit registration! Discounted rates expire this Friday, February 7. View registration and pricing options:

    Poništi
  17. proslijedio/la je Tweet
    3. velj

    "Call Me, Maybe" - Synlogic CEO reflects on pros/cons of the quarterly earnings call for young biotech companies as a new From The Trenches post.

    Poništi
  18. 31. sij

    These are the Massachusetts-based and companies that raised a total of $96.7 million this week:

    Poništi
  19. 31. sij
    Poništi
  20. 31. sij

    The first-ever Year-in-Review report for Boston was published yesterday. Have you taken a look yet?

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·